Deirdre P Cronin-Fenton1, Uffe Heide-Jørgensen, Thomas P Ahern, Timothy L Lash, Peer Christiansen, Bent Ejlertsen, Henrik T Sørensen. 1. From the aDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark; bDepartments of Surgery and Biochemistry, University of Vermont, Burlington, VT; cDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA; dBreast and Endocrine Section, Department of Surgery, Aarhus University Hospital, Aarhus, Denmark; eDanish Breast Cancer Cooperative Group, Copenhagen, Denmark; and fRigshospitalet, Copenhagen, Denmark.
Abstract
BACKGROUND: Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and selective COX-2 inhibitors may improve outcomes in breast cancer patients. We investigated the association of aspirin, NSAIDs, and use of selective COX-2 inhibitors with breast cancer recurrence. METHODS: We identified incident stage I-III Danish breast cancer patients in the Danish Breast Cancer Cooperative Group registry, who were diagnosed during 1996-2008. Prescriptions for aspirin (>99% low-dose aspirin), NSAIDs, and selective COX-2 inhibitors were ascertained from the National Prescription Registry. Follow-up began on the date of breast cancer primary surgery and continued until the first of recurrence, death, emigration, or 1 January 2013. We used Cox regression models to compute hazard ratios (HR) and corresponding 95% confidence intervals (95% CI) associating prescriptions with recurrence, adjusting for confounders. RESULTS: We identified 34,188 breast cancer patients with 233,130 person-years of follow-up. Median follow-up was 7.1 years; 5,325 patients developed recurrent disease. Use of aspirin, NSAIDs, or selective COX-2 inhibitors was not associated with the rate of recurrence (HRadjusted aspirin = 1.0, 95% CI = 0.90, 1.1; NSAIDs = 0.99, 95% CI = 0.92, 1.1; selective COX-2 inhibitors = 1.1, 95% CI = 0.98, 1.2), relative to nonuse. Prediagnostic use of the exposure drugs was associated with reduced recurrence rates (HRaspirin = 0.92, 95% CI = 0.82, 1.0; HRNSAIDs = 0.86, 95% CI = 0.81, 0.91; HRsCOX-2inhibitors = 0.88, 95% CI = 0.83, 0.95). CONCLUSIONS: This prospective cohort study suggests that post diagnostic prescriptions for aspirin, NSAIDs, and selective COX-2 inhibitors have little or no association with the rate of breast cancer recurrence. Prediagnostic use of the drugs was, however, associated with a reduced rate of breast cancer recurrence.
BACKGROUND:Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and selective COX-2 inhibitors may improve outcomes in breast cancerpatients. We investigated the association of aspirin, NSAIDs, and use of selective COX-2 inhibitors with breast cancer recurrence. METHODS: We identified incident stage I-III Danish breast cancerpatients in the Danish Breast Cancer Cooperative Group registry, who were diagnosed during 1996-2008. Prescriptions for aspirin (>99% low-dose aspirin), NSAIDs, and selective COX-2 inhibitors were ascertained from the National Prescription Registry. Follow-up began on the date of breast cancer primary surgery and continued until the first of recurrence, death, emigration, or 1 January 2013. We used Cox regression models to compute hazard ratios (HR) and corresponding 95% confidence intervals (95% CI) associating prescriptions with recurrence, adjusting for confounders. RESULTS: We identified 34,188 breast cancerpatients with 233,130 person-years of follow-up. Median follow-up was 7.1 years; 5,325 patients developed recurrent disease. Use of aspirin, NSAIDs, or selective COX-2 inhibitors was not associated with the rate of recurrence (HRadjusted aspirin = 1.0, 95% CI = 0.90, 1.1; NSAIDs = 0.99, 95% CI = 0.92, 1.1; selective COX-2 inhibitors = 1.1, 95% CI = 0.98, 1.2), relative to nonuse. Prediagnostic use of the exposure drugs was associated with reduced recurrence rates (HRaspirin = 0.92, 95% CI = 0.82, 1.0; HRNSAIDs = 0.86, 95% CI = 0.81, 0.91; HRsCOX-2inhibitors = 0.88, 95% CI = 0.83, 0.95). CONCLUSIONS: This prospective cohort study suggests that post diagnostic prescriptions for aspirin, NSAIDs, and selective COX-2 inhibitors have little or no association with the rate of breast cancer recurrence. Prediagnostic use of the drugs was, however, associated with a reduced rate of breast cancer recurrence.
Authors: Thomas P Ahern; Lars Pedersen; Maja Tarp; Deirdre P Cronin-Fenton; Jens Peter Garne; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash Journal: J Natl Cancer Inst Date: 2011-08-02 Impact factor: 13.506
Authors: Johanna G H van Nes; Esther M de Kruijf; Dana Faratian; Cornelis J H van de Velde; Hein Putter; Claire Falconer; Vincent T H B M Smit; Charlene Kay; Marc J van de Vijver; Peter J K Kuppen; John M S Bartlett Journal: Breast Cancer Res Treat Date: 2010-04-01 Impact factor: 4.872
Authors: M Schmidt; M B Johansen; T L Lash; C F Christiansen; S Christensen; H T Sørensen Journal: J Thromb Haemost Date: 2010-03-12 Impact factor: 5.824
Authors: Hee Sung Kim; Hyeong-Gon Moon; Wonshik Han; Cha Kyung Yom; Woo Ho Kim; Jun Ho Kim; Dong-Young Noh Journal: Breast Cancer Res Treat Date: 2011-04-28 Impact factor: 4.872
Authors: H T Sørensen; L Mellemkjaer; W J Blot; G L Nielsen; F H Steffensen; J K McLaughlin; J H Olsen Journal: Am J Gastroenterol Date: 2000-09 Impact factor: 10.864
Authors: B B Weksler; S B Pett; D Alonso; R C Richter; P Stelzer; V Subramanian; K Tack-Goldman; W A Gay Journal: N Engl J Med Date: 1983-04-07 Impact factor: 91.245
Authors: Jack Cuzick; Florian Otto; John A Baron; Powel H Brown; John Burn; Peter Greenwald; Janusz Jankowski; Carlo La Vecchia; Frank Meyskens; Hans Jörg Senn; Michael Thun Journal: Lancet Oncol Date: 2009-05 Impact factor: 41.316
Authors: Rita D Brandão; Jürgen Veeck; Koen K Van de Vijver; Patrick Lindsey; Bart de Vries; Catharina H M J van Elssen; Marinus J Blok; Kristien Keymeulen; Torik Ayoubi; Hubert J M Smeets; Vivianne C Tjan-Heijnen; Pierre S Hupperets Journal: Breast Cancer Res Date: 2013-04-08 Impact factor: 6.466
Authors: R N Pedersen; K Bhaskaran; U Heide-Jørgensen; M Nørgaard; P M Christiansen; N Kroman; H T Sørensen; D P Cronin-Fenton Journal: Br J Surg Date: 2017-08-07 Impact factor: 6.939